BIG Pharmacy, in collaboration with Pfizer Malaysia, successfully organized an engaging webinar on Apixaban, attracting over 100 participants from across the healthcare community. The session focused on advancing knowledge in stroke prevention for atrial fibrillation (AF) and the expanding role of direct oral anticoagulants (DOACs).
Addressing Stroke Risk in Atrial Fibrillation
Atrial fibrillation is the most common sustained cardiac arrhythmia, associated with a five-fold increase in stroke risk. Early diagnosis and effective anticoagulation are essential in reducing complications. The webinar provided updates on clinical guidelines, real-world data, and best practices for managing AF patients.
Why Apixaban?
Speakers highlighted the clinical benefits of Apixaban, a direct Factor Xa inhibitor, widely recognized as a preferred DOAC for AF and venous thromboembolism (VTE). Key points included:
- Proven Efficacy: Superior protection against stroke and systemic embolism compared to warfarin.
- Lower Bleeding Risk: Favorable safety profile, especially in elderly and chronic kidney disease patients.
- Patient Convenience: Fixed dosing without the need for routine INR monitoring.
Empowering Pharmacists and Healthcare Professionals
The webinar emphasized the role of pharmacists in ensuring treatment success:
- Educating patients on medication adherence and correct dosing.
- Identifying drug interactions and monitoring renal function.
- Supporting lifestyle modifications to optimize long-term outcomes.
Strong Engagement and Knowledge Sharing
With more than 100 participants, the interactive session showcased the enthusiasm of pharmacists, doctors, and healthcare providers in expanding their clinical knowledge. The Q&A segment allowed participants to clarify practical challenges and share real-world experiences.
BIG Pharmacy’s Commitment to Education
This event reflects BIG Pharmacy’s dedication to continuous professional development (CPD) and its mission to support healthcare providers with the latest evidence-based updates. Partnering with global leaders like Pfizer ensures that the pharmacy community is well-equipped to deliver better patient care.
Conclusion
The Apixaban webinar by BIG Pharmacy and Pfizer was a resounding success, enriching participants’ understanding of anticoagulation therapy in atrial fibrillation and VTE. With strong participation and expert insights, the event reinforced the importance of ongoing education in improving cardiovascular outcomes.